O gigante farmacêutico suíço
Novartis anunciou hoje (21) a compra da norte-americana Selexys Pharmaceuticals
Corp., um laboratório de investigação sobre sangue e doenças inflamatórias.
O negócio está avaliado em até
665 milhões de dólares (627 milhões de euros).
Em comunicado, a Novartis
refere que a compra da Selexys surgiu depois de ver os resultados dos testes,
com uma ampla amostra, a um medicamento para tratar a dor de pessoas que
padecem de falciforme, um tipo de anemia em que a empresa é especializada.
Dinheiro Digital / Lusa
Novartis acquires Selexys Pharmaceuticals Corporation
and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD)
· Deal
followed results of Phase II SUSTAIN study of SelG1 in reduction of
vaso-occlusive pain crises, a major complication of SCD with limited treatment
options
· Results
of SUSTAIN will be presented in the Plenary Scientific Session at the 58th American
Society of Hematology (ASH) Annual Meeting
· Acquisition
complements and broadens Novartis' hematology pipeline and underscores
commitment to improving care for patients with high unmet need
Basel, November 21, 2016 - Novartis today
announced it has acquired Selexys Pharmaceuticals Corporation, a company
specializing in development of therapeutics in certain hematologic and
inflammatory disorders. Novartis exercised its right to acquire Selexys
following receipt of results of the SUSTAIN study, a Phase II trial evaluating
the use of SelG1, an anti-P-selectin antibody, in the reduction of
vaso-occlusive pain crises in patients with sickle cell disease (SCD). Results
from the study will be presented during the Plenary Scientific Session at the
58thAmerican Society of Hematology (ASH) Annual Meeting on December
4, 2016, in San Diego, California.
"Sickle cell disease affects millions of people
around the world and there are limited therapies available for treatment of
vaso-occlusive pain crises, a very common complication of the disease,"
said Bruno Strigini, CEO of Novartis Oncology. "With this acquisition,
Novartis is able to leverage its leadership in hematology research to advance
development of a potential new treatment option for patients living with this
debilitating condition."
SCD is a hereditary blood disorder characterized by
sickle-shaped red blood cells[1]. It is a life-long disease with many forms
that can range in clinical severity from asymptomatic to life-threatening.[1]
Vaso-occlusive crises, or pain crises, are the major reason for health care
encounters in SCD and occur episodically when sickle-shaped red blood cells
block blood flow through blood vessels.[2],[3]
"We would like to extend our gratitude to all of
the dedicated patients, physicians and nurses who participated in the SUSTAIN
study of SelG1 in sickle cell disease," said Dr. Scott Rollins, former
President and Chief Executive Officer of Selexys Pharmaceuticals.
"Further, the acquisition of Selexys by Novartis represents an important
step in the continued development of SelG1, a novel, potential first-in-class
therapy for patients with this underserved life-threatening disease."
Novartis obtained the exclusive right to acquire
Selexys and SelG1 in 2012. Prior to the acquisition, Selexys Pharmaceutical
Corporation was a privately held biopharmaceutical company headquartered in
Oklahoma City, Oklahoma. Terms of the deal could total up to $665 million in
upfront, acquisition and milestone payments.
0 comentários:
Postar um comentário